Compare NetFlix Inc (NFLX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs Tango Therapeutics Inc. — how do they compare? NetFlix Inc trades at $71.2 (market cap $293.85B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: NetFlix Inc is far larger — about 78.6× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 126 Days and Tango Therapeutics Inc. for 0 Days on average.
| NFLX | TNGX | |
|---|---|---|
Market Cap | $293.85B | $3.74B |
Volume | 39,920,482 | 3,438,781 |
Sector | Media | Health |
52-Week High | $124.13 | $32.90 |
52-Week Low | $67.06 | $7.50 |
Typical Hold Time | 126 Days | 0 Days |
Enterprise Value | $299.03B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $70.48, down 0.18% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals with Q2 2026 EPS of $0.80 beating expectations, revenue of $45.18B in 2025, and a net income margin of 28.22%. Recent news highlights strategic moves into live sports and content expansion, while analyst consensus remains bullish with a $89.39 price target.
The outlook for NFLX is positive due to robust earnings growth and expanding profitability, but risks include competitive pressures and market volatility. The stock offers potential upside based on analyst targets, supported by strong cash flow and institutional interest, though investors should monitor execution on live content initiatives.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
